RT info:eu-repo/semantics/article
T1 Systematic review and meta-analysis provide no guidance on management of asymptomatic bacteriuria within the first year after kidney transplantation
A1 Medina Polo, José
A1 Falkensammer, Eva
A1 Köves, Béla
A1 Kranz, Jennifer
A1 Tandogdu, Zafer
A1 Tapia Herrero, Ana María
A1 Cai, Tommaso
A1 Wagenlehner, Florian M. E.
A1 Schneidewind, Laila
A1 Bjerklund Johansen, Truls Erik
K1 Antibiotics
K1 Antibióticos
K1 Urologic diseases
K1 Urinario, Aparato - Enfermedades - Tratamiento
K1 Urology
K1 Nephrology
K1 Kidneys - Diseases
K1 Riñones - Enfermedades
K1 Kidneys - Transplantation
K1 Riñones - Trasplante
K1 Urinary tract infections
K1 Vías urinarias - Infecciones
K1 Insuficiencia renal aguda
K1 Acute renal failure
K1 Meta-analysis
K1 Systematic reviews (Medical research)
K1 Medicina - Investigación
K1 Public health
K1 3213.16 Urología
K1 3205.06 Nefrología
K1 32 Ciencias Médicas
K1 3212 Salud Publica
AB (1) Background: Urinary tract infections (UTIs) are among the most frequent complications in kidney transplant (KT) recipients. Asymptomatic bacteriuria (ASB) may be a risk factor for UTIs and graft rejection. We aimed to evaluate available evidence regarding the benefit of screening and treatment of ASB within the first year after KT. (2) Evidence acquisition: A systematic literature search was conducted in MEDLINE, the Cochrane Library CENTRAL and Embase. Inclusion criteria were manuscripts in English addressing the management of ASB after KT. The PICO questions concerned Patients (adults receiving a KT), Intervention (screening, diagnosis and treatment of ASB), Control (screening and no antibiotic treatment) and Outcome (UTIs, sepsis, kidney failure and death). (3) Evidence synthesis: The systematic review identified 151 studies, and 16 full-text articles were evaluated. Seven were excluded because they did not evaluate the effect of treatment of ASB. There was no evidence for a higher incidence of lower UTIs, acute pyelonephritis, graft loss, or mortality in patients not treated with antibiotics for ASB. Analysis of comparative non-randomized and observational studies did not provide supplementary evidence to guide clinical recommendations. We believe this lack of evidence is due to confounding risk factors that are not being considered in the stratification of study patients.
PB MDPI
SN 2079-6382
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/70300
UL https://uvadoc.uva.es/handle/10324/70300
LA eng
NO Antibiotics, 2024, Vol. 13, Nº. 5, 442
NO Producción Científica
DS UVaDOC
RD 21-dic-2024